NASDAQ:CRMD CorMedix (CRMD) Stock Price, News & Analysis $12.53 +0.17 (+1.38%) Closing price 05/27/2025 04:00 PM EasternExtended Trading$12.45 -0.08 (-0.64%) As of 05:03 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About CorMedix Stock (NASDAQ:CRMD) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get CorMedix alerts:Sign Up Key Stats Today's Range$12.35▼$12.9950-Day Range$5.86▼$12.8252-Week Range$3.61▼$13.85Volume1.60 million shsAverage Volume1.16 million shsMarket Capitalization$849.85 millionP/E RatioN/ADividend YieldN/APrice Target$15.00Consensus RatingBuy Company OverviewCorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.Read More… CorMedix Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks43rd Percentile Overall ScoreCRMD MarketRank™: CorMedix scored higher than 43% of companies evaluated by MarketBeat, and ranked 597th out of 920 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingBuy Consensus RatingCorMedix has received a consensus rating of Buy. The company's average rating score is 3.14, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCorMedix has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about CorMedix's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for CorMedix are expected to grow in the coming year, from ($0.32) to $0.94 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of CorMedix is -15.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of CorMedix is -15.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCorMedix has a P/B Ratio of 9.79. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about CorMedix's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted11.85% of the outstanding shares of CorMedix have been sold short.Short Interest Ratio / Days to CoverCorMedix has a short interest ratio ("days to cover") of 4.6.Change versus previous monthShort interest in CorMedix has recently decreased by 2.66%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCorMedix does not currently pay a dividend.Dividend GrowthCorMedix does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted11.85% of the outstanding shares of CorMedix have been sold short.Short Interest Ratio / Days to CoverCorMedix has a short interest ratio ("days to cover") of 4.6.Change versus previous monthShort interest in CorMedix has recently decreased by 2.66%, indicating that investor sentiment is improving. News and Social Media4.0 / 5News Sentiment1.23 News SentimentCorMedix has a news sentiment score of 1.23. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.03 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for CorMedix this week, compared to 4 articles on an average week.Search Interest9 people have searched for CRMD on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat Follows8 people have added CorMedix to their MarketBeat watchlist in the last 30 days. This is an increase of 700% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, CorMedix insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.20% of the stock of CorMedix is held by insiders.Percentage Held by InstitutionsOnly 34.18% of the stock of CorMedix is held by institutions.Read more about CorMedix's insider trading history. Receive CRMD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CorMedix and its competitors with MarketBeat's FREE daily newsletter. Email Address CRMD Stock News HeadlinesAnalysts Set CorMedix Inc. (NASDAQ:CRMD) Target Price at $15.00May 24, 2025 | americanbankingnews.comCorMedix at RBC Capital Markets: Strategic Expansion and GrowthMay 23, 2025 | investing.com3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are mere days away from a critical announcement from a key tech leader… One that will officially ignite “AI 2.0” – and potentially send a whole new class of stocks soaring. May 28, 2025 | Timothy Sykes (Ad)Contrasting CorMedix (NASDAQ:CRMD) & Abbott Laboratories (NYSE:ABT)May 19, 2025 | americanbankingnews.comCorMedix Inc. to Participate in the RBC Global Healthcare ConferenceMay 15, 2025 | globenewswire.comCorMedix Inc. (CRMD): Among Billionaire Paul Singer’s Stock Picks with Huge Upside PotentialMay 10, 2025 | finance.yahoo.comCorMedix Inc. (CRMD): Among Billionaire Paul Singer’s Stock Picks with Huge Upside PotentialMay 9, 2025 | insidermonkey.comAnalysts Just Shipped A Substantial Upgrade To Their CorMedix Inc. (NASDAQ:CRMD) EstimatesMay 8, 2025 | finance.yahoo.comSee More Headlines CRMD Stock Analysis - Frequently Asked Questions How have CRMD shares performed this year? CorMedix's stock was trading at $8.10 on January 1st, 2025. Since then, CRMD stock has increased by 54.7% and is now trading at $12.53. View the best growth stocks for 2025 here. How were CorMedix's earnings last quarter? CorMedix Inc. (NASDAQ:CRMD) issued its quarterly earnings results on Tuesday, May, 6th. The company reported $0.30 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.25 by $0.05. The company earned $39.08 million during the quarter, compared to the consensus estimate of $38.90 million. Read the conference call transcript. When did CorMedix's stock split? CorMedix shares reverse split on the morning of Tuesday, March 26th 2019. The 1-5 reverse split was announced on Thursday, March 21st 2019. The number of shares owned by shareholders was adjusted after the closing bell on Monday, March 25th 2019. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split. Who are CorMedix's major shareholders? CorMedix's top institutional investors include Vanguard Group Inc. (5.38%), Elliott Investment Management L.P. (3.60%), Palisades Investment Partners LLC (0.55%) and Invesco Ltd. (0.43%). Insiders that own company stock include Joseph Todisco, Erin Mistry and Elizabeth Hurlburt. View institutional ownership trends. How do I buy shares of CorMedix? Shares of CRMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of CorMedix own? Based on aggregate information from My MarketBeat watchlists, some other companies that CorMedix investors own include Voyager Therapeutics (VYGR), Waste Connections (WCN), American Water Works (AWK), DiamondRock Hospitality (DRH), AUO (AUOTY), Marinus Pharmaceuticals (MRNS) and The RMR Group (RMR). Company Calendar Last Earnings5/06/2025Today5/28/2025Next Earnings (Estimated)8/13/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CRMD CIK1410098 Webwww.cormedix.com Phone(908) 517-9500Fax908-429-4307Employees30Year FoundedN/APrice Target and Rating Average Stock Price Target$15.00 High Stock Price Target$18.00 Low Stock Price Target$12.00 Potential Upside/Downside+19.7%Consensus RatingBuy Rating Score (0-4)3.14 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)$0.22 Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$46.34 million Net MarginsN/A Pretax Margin-387.73% Return on Equity-79.21% Return on Assets-64.68% Debt Debt-to-Equity RatioN/A Current Ratio3.96 Quick Ratio3.60 Sales & Book Value Annual Sales$82.55 million Price / Sales10.29 Cash FlowN/A Price / Cash FlowN/A Book Value$1.28 per share Price / Book9.79Miscellaneous Outstanding Shares67,825,000Free Float57,522,000Market Cap$849.85 million OptionableOptionable Beta1.54 Free Today: Your Guide to Smarter Options TradesLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:CRMD) was last updated on 5/28/2025 by MarketBeat.com Staff From Our PartnersTrump Predicts Dollar DownfallREAD THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... ...Augusta Precious Metals | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredF1 Engineering Powers This Electric Marine MotorThe future of marine propulsion has arrived - powered by F-1 grade engineering. In collaboration with McLar...The Tomorrow Investor | SponsoredBig Oil’s big pivotThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CorMedix Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CorMedix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.